ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1115

The Effect of ESKD on COVID-19 In-Hospital Mortality

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Manadan, Neil, Rush Nephrology, Chicago, Illinois, United States
  • Manadan, Jay, Rush Nephrology, Chicago, Illinois, United States
  • Patel, Nilam, Rush Nephrology, Chicago, Illinois, United States
  • Whittier, William Luke, Rush Nephrology, Chicago, Illinois, United States

Significant morbidity resulted when the COVID-19 infection became a pandemic in the United States. This study aimed to study the effect of end stage kidney disease (ESKD) on mortality on those with COVID.


We performed a retrospective analysis of all adult hospitalizations with a principal diagnosis of COVID from the 2020 National Inpatient Sample (NIS) database. They were subdivided in those with and without ESKD. Variables with a p value ≤0.2 in the univariable screen were included in a multivariable analysis for in-hospital death.


There were 27,668,666 adult hospitalizations in the 2020 NIS database. Of those, 1,011,340 had COVID without ESKD and 38,705 had COVID with ESKD (figure 1). Among COVID inpatients, univariable analysis showed an association for death for the following variables: age, CCI, male gender, White, African American, Hispanic, Native Americans, ESKD, Income Q1, and Income Q3. Multivariable analysis showed higher odds for death for the following variables: Age (OR 1.04; p<0.001), CCI (OR 1.18; p<0.001), Male (OR 1.39; p<0.001), Hispanics (OR 1.09; p= 0.019), Native American (OR 1.57; p<0.001), ESKD (OR 1.25; p<0.001), and Income Q1 (OR 1.12; p<0.001) (figure 2).


Age, CCI, male gender, Hispanic race, Native American ethnicity, ESKD, and a lower income were associated with higher odds of death among those hospitalized with COVID. This information can alert clinicians of the negative effects of ESKD on COVID mortality. Further studies on COVID mortality must account for ESKD.

Figure 1

Figure 2